Lincoln Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 28, 2025, 8:00 pm

Market Cap	1,131 Cr.
Current Price	565
High / Low	980/499
Stock P/E	13.7
Book Value	335
Dividend Yield	0.32 %
ROCE	17.6 %
ROE	13.0 %
Face Value	10.0
PEG Ratio	2.39

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Lincoln Pharmaceuticals Ltd

Competitors of Lincoln Pharmaceuticals Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.48 Cr.	2.87	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.4 Cr.	55.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	37.7 Cr.	25.7	29.1/13.1	37.0	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,932.63 Cr	1,189.38		102.13	194.43	0.31%	16.64%	15.19%	6.18

All Competitor Stocks of Lincoln Pharmaceuticals Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	103	123	141	134	112	136	156	146	142	147	161	147	168
Expenses	85	107	112	107	96	115	125	117	124	125	133	123	141
Operating Profit	17	17	29	27	17	21	31	30	18	23	28	24	27
OPM %	17%	14%	21%	20%	15%	15%	20%	20%	13%	15%	18%	16%	16%
Other Income	2	6	6	6	4	8	9	11	7	10	10	9	-7
Interest	1	0	0	0	1	0	0	0	0	0	0	1	0
Depreciation	2	2	2	2	2	3	3	3	3	3	3	3	3
Profit before tax	17	21	32	31	17	25	37	38	22	29	35	29	16
Tax %	34%	28%	26%	29%	26%	25%	25%	26%	16%	20%	24%	28%	29%
Net Profit	11	15	24	22	13	19	28	28	19	24	26	21	12
EPS in Rs	5.50	7.49	11.84	10.79	6.27	9.49	13.80	14.00	9.29	11.82	13.15	10.37	5.78

Last Updated: May 31, 2025, 8:35 am

Below is a detailed analysis of the quarterly data for Lincoln Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 168.00 Cr.. The value appears strong and on an upward trend. It has increased from 147.00 Cr. (Dec 2024) to 168.00 Cr., marking an increase of 21.00 Cr..
For Expenses, as of Mar 2025, the value is 141.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 123.00 Cr. (Dec 2024) to 141.00 Cr., marking an increase of 18.00 Cr..
For Operating Profit, as of Mar 2025, the value is 27.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Dec 2024) to 27.00 Cr., marking an increase of 3.00 Cr..
For OPM %, as of Mar 2025, the value is 16.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 16.00%.
For Other Income, as of Mar 2025, the value is -7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Dec 2024) to -7.00 Cr., marking a decrease of 16.00 Cr..
For Interest, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Dec 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 3.00 Cr..
For Profit before tax, as of Mar 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 29.00 Cr. (Dec 2024) to 16.00 Cr., marking a decrease of 13.00 Cr..
For Tax %, as of Mar 2025, the value is 29.00%. The value appears to be increasing, which may not be favorable. It has increased from 28.00% (Dec 2024) to 29.00%, marking an increase of 1.00%.
For Net Profit, as of Mar 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Dec 2024) to 12.00 Cr., marking a decrease of 9.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 5.78. The value appears to be declining and may need further review. It has decreased from 10.37 (Dec 2024) to 5.78, marking a decrease of 4.59.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:55 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	210	266	400	360	361	366	386	424	472	510	581	623
Expenses	190	240	359	313	308	299	321	337	376	421	480	522
Operating Profit	20	26	41	47	53	68	66	87	96	90	100	101
OPM %	10%	10%	10%	13%	15%	18%	17%	21%	20%	18%	17%	16%
Other Income	2	7	7	2	5	5	11	5	10	22	34	22
Interest	7	8	10	7	5	4	2	2	1	2	1	2
Depreciation	4	5	5	6	6	7	7	8	8	9	11	13
Profit before tax	12	20	33	37	46	62	67	84	96	100	122	109
Tax %	16%	24%	28%	25%	25%	22%	23%	26%	28%	27%	24%	25%
Net Profit	10	15	24	28	35	49	51	62	69	73	93	82
EPS in Rs	6.53	9.20	14.52	14.06	17.31	24.36	25.72	31.12	34.63	36.40	46.58	41.11
Dividend Payout %	9%	11%	7%	9%	9%	6%	6%	5%	4%	4%	4%	4%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	50.00%	60.00%	16.67%	25.00%	40.00%	4.08%	21.57%	11.29%	5.80%	27.40%	-11.83%
Change in YoY Net Profit Growth (%)	0.00%	10.00%	-43.33%	8.33%	15.00%	-35.92%	17.49%	-10.28%	-5.49%	21.60%	-39.23%

Lincoln Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	9%
5 Years:	10%
3 Years:	10%
TTM:	7%

Compounded Profit Growth
10 Years:	19%
5 Years:	10%
3 Years:	6%
TTM:	-11%

Stock Price CAGR
10 Years:	21%
5 Years:	29%
3 Years:	25%
1 Year:	-13%

Return on Equity
10 Years:	17%
5 Years:	16%
3 Years:	15%
Last Year:	13%

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:47 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	16	16	16	20	20	20	20	20	20	20	20	20
Reserves	82	95	124	172	204	249	293	346	413	482	573	652
Borrowings	68	76	78	64	61	34	5	1	2	2	1	-0
Other Liabilities	93	70	56	48	62	63	71	85	99	83	106	125
Total Liabilities	260	258	275	305	347	366	389	452	534	587	700	797
Fixed Assets	65	66	98	103	117	121	123	111	132	151	179	182
CWIP	2	3	3	7	0	2	0	2	16	7	3	4
Investments	0	0	0	10	11	18	34	81	97	91	139	174
Other Assets	192	190	174	186	219	225	232	259	290	339	379	437
Total Assets	260	258	275	305	347	366	389	452	534	587	700	797

Below is a detailed analysis of the balance sheet data for Lincoln Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 20.00 Cr..
For Reserves, as of Mar 2025, the value is 652.00 Cr.. The value appears strong and on an upward trend. It has increased from 573.00 Cr. (Mar 2024) to 652.00 Cr., marking an increase of 79.00 Cr..
For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 125.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 106.00 Cr. (Mar 2024) to 125.00 Cr., marking an increase of 19.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 797.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 700.00 Cr. (Mar 2024) to 797.00 Cr., marking an increase of 97.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 182.00 Cr.. The value appears strong and on an upward trend. It has increased from 179.00 Cr. (Mar 2024) to 182.00 Cr., marking an increase of 3.00 Cr..
For CWIP, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
For Investments, as of Mar 2025, the value is 174.00 Cr.. The value appears strong and on an upward trend. It has increased from 139.00 Cr. (Mar 2024) to 174.00 Cr., marking an increase of 35.00 Cr..
For Other Assets, as of Mar 2025, the value is 437.00 Cr.. The value appears strong and on an upward trend. It has increased from 379.00 Cr. (Mar 2024) to 437.00 Cr., marking an increase of 58.00 Cr..
For Total Assets, as of Mar 2025, the value is 797.00 Cr.. The value appears strong and on an upward trend. It has increased from 700.00 Cr. (Mar 2024) to 797.00 Cr., marking an increase of 97.00 Cr..

Notably, the Reserves (652.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	5	25	45	25	27	53	75	69	76	39	63	93
Cash from Investing Activity +	1	7	-42	-25	-12	-18	-31	-64	-78	-37	-57	-79
Cash from Financing Activity +	-11	-32	-3	0	-11	-36	-38	-6	-3	-4	-5	-6
Net Cash Flow	-4	-1	-0	-0	3	-1	7	-1	-4	-2	1	8

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-48.00	-50.00	-37.00	-17.00	-8.00	34.00	61.00	86.00	94.00	88.00	99.00	101.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	140	154	163	73	92	111	122	96	98	90	98	102
Inventory Days	54	62	44	36	63	86	75	95	86	121	106	101
Days Payable	133	174	92	40	54	82	92	102	105	120	77	95
Cash Conversion Cycle	62	43	116	70	100	115	106	88	78	91	126	108
Working Capital Days	84	97	145	79	115	138	143	130	119	115	123	128
ROCE %	11%	11%	15%	22%	19%	19%	23%	22%	25%	24%	22%	22%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	42.05%	44.08%	44.09%	46.34%	47.00%	48.68%	50.53%	49.81%	49.54%	49.78%	49.78%	49.78%
FIIs	0.77%	0.64%	0.63%	1.44%	1.27%	1.74%	2.59%	3.22%	3.93%	3.95%	5.19%	5.16%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.05%	0.04%	0.00%	0.00%
Public	57.19%	55.28%	55.29%	52.22%	51.74%	49.57%	46.87%	46.92%	46.49%	46.24%	45.04%	45.07%
No. of Shareholders	32,447	31,902	31,731	29,846	29,088	27,480	28,670	29,316	31,375	29,967	31,330	31,848

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Motilal Oswal S&P BSE Healthcare ETF	106	0.08	0.01	106	2025-04-22 17:25:28	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	46.58	36.40	34.63	31.11	25.72
Diluted EPS (Rs.)	46.58	36.40	34.63	31.11	25.72
Cash EPS (Rs.)	51.89	40.97	38.66	34.91	29.40
Book Value[Excl.RevalReserv]/Share (Rs.)	295.98	250.86	216.12	187.85	156.74
Book Value[Incl.RevalReserv]/Share (Rs.)	295.98	250.86	216.12	187.85	156.74
Revenue From Operations / Share (Rs.)	289.84	254.78	235.71	212.09	193.25
PBDIT / Share (Rs.)	67.07	55.76	52.66	46.42	38.29
PBIT / Share (Rs.)	61.76	51.18	48.62	42.64	34.63
PBT / Share (Rs.)	61.03	50.16	47.90	41.86	33.62
Net Profit / Share (Rs.)	46.58	36.40	34.63	31.12	25.73
NP After MI And SOA / Share (Rs.)	46.58	36.40	34.63	31.11	25.72
PBDIT Margin (%)	23.13	21.88	22.34	21.88	19.81
PBIT Margin (%)	21.30	20.08	20.62	20.10	17.91
PBT Margin (%)	21.05	19.68	20.32	19.73	17.39
Net Profit Margin (%)	16.07	14.28	14.69	14.67	13.31
NP After MI And SOA Margin (%)	16.07	14.28	14.69	14.66	13.30
Return on Networth / Equity (%)	15.73	14.50	16.02	16.58	16.42
Return on Capital Employeed (%)	20.34	19.89	21.94	22.10	21.38
Return On Assets (%)	13.32	12.41	12.97	13.54	13.21
Total Debt / Equity (X)	0.00	0.00	0.00	0.00	0.01
Asset Turnover Ratio (%)	0.90	0.90	0.95	0.99	1.03
Current Ratio (X)	4.84	5.08	3.90	4.17	3.78
Quick Ratio (X)	4.00	4.11	3.10	3.53	3.06
Inventory Turnover Ratio (X)	2.73	2.48	2.66	2.18	2.76
Dividend Payout Ratio (NP) (%)	3.22	4.12	4.32	0.00	11.66
Dividend Payout Ratio (CP) (%)	2.89	3.66	3.87	0.00	10.21
Earning Retention Ratio (%)	96.78	95.88	95.68	0.00	88.34
Cash Earning Retention Ratio (%)	97.11	96.34	96.13	0.00	89.79
Interest Coverage Ratio (X)	91.70	55.01	72.68	59.44	37.95
Interest Coverage Ratio (Post Tax) (X)	64.69	36.91	48.79	40.86	26.51
Enterprise Value (Cr.)	1159.77	646.08	574.49	436.11	258.08
EV / Net Operating Revenue (X)	2.00	1.27	1.22	1.03	0.66
EV / EBITDA (X)	8.63	5.79	5.45	4.70	3.37
MarketCap / Net Operating Revenue (X)	2.02	1.33	1.32	1.06	0.69
Retention Ratios (%)	96.77	95.87	95.67	0.00	88.33
Price / BV (X)	1.98	1.35	1.44	1.20	0.85
Price / Net Operating Revenue (X)	2.02	1.33	1.32	1.06	0.69
EarningsYield	0.07	0.10	0.11	0.13	0.19

After reviewing the key financial ratios for Lincoln Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 46.58. This value is within the healthy range. It has increased from 36.40 (Mar 23) to 46.58, marking an increase of 10.18.
For Diluted EPS (Rs.), as of Mar 24, the value is 46.58. This value is within the healthy range. It has increased from 36.40 (Mar 23) to 46.58, marking an increase of 10.18.
For Cash EPS (Rs.), as of Mar 24, the value is 51.89. This value is within the healthy range. It has increased from 40.97 (Mar 23) to 51.89, marking an increase of 10.92.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 295.98. It has increased from 250.86 (Mar 23) to 295.98, marking an increase of 45.12.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 295.98. It has increased from 250.86 (Mar 23) to 295.98, marking an increase of 45.12.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 289.84. It has increased from 254.78 (Mar 23) to 289.84, marking an increase of 35.06.
For PBDIT / Share (Rs.), as of Mar 24, the value is 67.07. This value is within the healthy range. It has increased from 55.76 (Mar 23) to 67.07, marking an increase of 11.31.
For PBIT / Share (Rs.), as of Mar 24, the value is 61.76. This value is within the healthy range. It has increased from 51.18 (Mar 23) to 61.76, marking an increase of 10.58.
For PBT / Share (Rs.), as of Mar 24, the value is 61.03. This value is within the healthy range. It has increased from 50.16 (Mar 23) to 61.03, marking an increase of 10.87.
For Net Profit / Share (Rs.), as of Mar 24, the value is 46.58. This value is within the healthy range. It has increased from 36.40 (Mar 23) to 46.58, marking an increase of 10.18.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 46.58. This value is within the healthy range. It has increased from 36.40 (Mar 23) to 46.58, marking an increase of 10.18.
For PBDIT Margin (%), as of Mar 24, the value is 23.13. This value is within the healthy range. It has increased from 21.88 (Mar 23) to 23.13, marking an increase of 1.25.
For PBIT Margin (%), as of Mar 24, the value is 21.30. This value exceeds the healthy maximum of 20. It has increased from 20.08 (Mar 23) to 21.30, marking an increase of 1.22.
For PBT Margin (%), as of Mar 24, the value is 21.05. This value is within the healthy range. It has increased from 19.68 (Mar 23) to 21.05, marking an increase of 1.37.
For Net Profit Margin (%), as of Mar 24, the value is 16.07. This value exceeds the healthy maximum of 10. It has increased from 14.28 (Mar 23) to 16.07, marking an increase of 1.79.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 16.07. This value is within the healthy range. It has increased from 14.28 (Mar 23) to 16.07, marking an increase of 1.79.
For Return on Networth / Equity (%), as of Mar 24, the value is 15.73. This value is within the healthy range. It has increased from 14.50 (Mar 23) to 15.73, marking an increase of 1.23.
For Return on Capital Employeed (%), as of Mar 24, the value is 20.34. This value is within the healthy range. It has increased from 19.89 (Mar 23) to 20.34, marking an increase of 0.45.
For Return On Assets (%), as of Mar 24, the value is 13.32. This value is within the healthy range. It has increased from 12.41 (Mar 23) to 13.32, marking an increase of 0.91.
For Total Debt / Equity (X), as of Mar 24, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.90. There is no change compared to the previous period (Mar 23) which recorded 0.90.
For Current Ratio (X), as of Mar 24, the value is 4.84. This value exceeds the healthy maximum of 3. It has decreased from 5.08 (Mar 23) to 4.84, marking a decrease of 0.24.
For Quick Ratio (X), as of Mar 24, the value is 4.00. This value exceeds the healthy maximum of 2. It has decreased from 4.11 (Mar 23) to 4.00, marking a decrease of 0.11.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.73. This value is below the healthy minimum of 4. It has increased from 2.48 (Mar 23) to 2.73, marking an increase of 0.25.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 3.22. This value is below the healthy minimum of 20. It has decreased from 4.12 (Mar 23) to 3.22, marking a decrease of 0.90.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 2.89. This value is below the healthy minimum of 20. It has decreased from 3.66 (Mar 23) to 2.89, marking a decrease of 0.77.
For Earning Retention Ratio (%), as of Mar 24, the value is 96.78. This value exceeds the healthy maximum of 70. It has increased from 95.88 (Mar 23) to 96.78, marking an increase of 0.90.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 97.11. This value exceeds the healthy maximum of 70. It has increased from 96.34 (Mar 23) to 97.11, marking an increase of 0.77.
For Interest Coverage Ratio (X), as of Mar 24, the value is 91.70. This value is within the healthy range. It has increased from 55.01 (Mar 23) to 91.70, marking an increase of 36.69.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 64.69. This value is within the healthy range. It has increased from 36.91 (Mar 23) to 64.69, marking an increase of 27.78.
For Enterprise Value (Cr.), as of Mar 24, the value is 1,159.77. It has increased from 646.08 (Mar 23) to 1,159.77, marking an increase of 513.69.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.00. This value is within the healthy range. It has increased from 1.27 (Mar 23) to 2.00, marking an increase of 0.73.
For EV / EBITDA (X), as of Mar 24, the value is 8.63. This value is within the healthy range. It has increased from 5.79 (Mar 23) to 8.63, marking an increase of 2.84.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.02. This value is within the healthy range. It has increased from 1.33 (Mar 23) to 2.02, marking an increase of 0.69.
For Retention Ratios (%), as of Mar 24, the value is 96.77. This value exceeds the healthy maximum of 70. It has increased from 95.87 (Mar 23) to 96.77, marking an increase of 0.90.
For Price / BV (X), as of Mar 24, the value is 1.98. This value is within the healthy range. It has increased from 1.35 (Mar 23) to 1.98, marking an increase of 0.63.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.02. This value is within the healthy range. It has increased from 1.33 (Mar 23) to 2.02, marking an increase of 0.69.
For EarningsYield, as of Mar 24, the value is 0.07. This value is below the healthy minimum of 5. It has decreased from 0.10 (Mar 23) to 0.07, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Lincoln Pharmaceuticals Ltd as of July 2, 2025 is: 478.84

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of July 2, 2025, Lincoln Pharmaceuticals Ltd is Overvalued by 15.25% compared to the current share price 565.00

Intrinsic Value of Lincoln Pharmaceuticals Ltd as of July 2, 2025 is: 506.26

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of July 2, 2025, Lincoln Pharmaceuticals Ltd is Overvalued by 10.40% compared to the current share price 565.00

Last 5 Year EPS CAGR: 5.73%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 19.58%, which is a positive sign. The company has higher reserves (307.08 cr) compared to borrowings (32.67 cr), indicating strong financial stability. The company has shown consistent growth in sales (413.25 cr) and profit (65.67 cr) over the years.	The stock has a high average Working Capital Days of 118.00, which may not be favorable. The stock has a high average Cash Conversion Cycle of 91.92, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lincoln Pharmaceuticals Ltd:
1. Net Profit Margin: 16.07%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 20.34% (Industry Average ROCE: 16.64%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 15.73% (Industry Average ROE: 15.19%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 64.69
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 4
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 13.7 (Industry average Stock P/E: 102.13)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Lincoln Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 20/01/1995 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1995PLC024288 and registration number is 024288. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 623.23 Cr. and Equity Capital is Rs. 20.03 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Lincoln House, Ahmedabad Gujarat 380060	investor@lincolnpharma.com http://www.lincolnpharma.com

Management
Name	Position Held
Mr. Kishor M Shah	Non Executive Chairman
Mr. Mahendra G Patel	Managing Director
Mr. Hashmukh I Patel	Whole Time Director
Mr. Munjal M Patel	Whole Time Director
Mr. Ashish R Patel	Whole Time Director
Mr. Rajnikant G Patel	Non Executive Director
Mr. Nareshkumar Suthar	Independent Director
Mr. Saurin J Parikh	Independent Director
Ms. Seema Mehta	Independent Director

FAQ

What is the intrinsic value of Lincoln Pharmaceuticals Ltd?

Lincoln Pharmaceuticals Ltd's intrinsic value (as of 02 July 2025) is 478.84 — 15.25% lower the current market price of 565.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,131 Cr. market cap, FY2025-2026 high/low of 980/499, reserves of 652 Cr, and liabilities of 797 Cr.

What is the Market Cap of Lincoln Pharmaceuticals Ltd?

The Market Cap of Lincoln Pharmaceuticals Ltd is 1,131 Cr..

What is the current Stock Price of Lincoln Pharmaceuticals Ltd as on 02 July 2025?

The current stock price of Lincoln Pharmaceuticals Ltd as on 02 July 2025 is 565.

What is the High / Low of Lincoln Pharmaceuticals Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Lincoln Pharmaceuticals Ltd stocks is ₹980/499.

What is the Stock P/E of Lincoln Pharmaceuticals Ltd?

The Stock P/E of Lincoln Pharmaceuticals Ltd is 13.7.

What is the Book Value of Lincoln Pharmaceuticals Ltd?

The Book Value of Lincoln Pharmaceuticals Ltd is 335.

What is the Dividend Yield of Lincoln Pharmaceuticals Ltd?

The Dividend Yield of Lincoln Pharmaceuticals Ltd is 0.32 %.

What is the ROCE of Lincoln Pharmaceuticals Ltd?

The ROCE of Lincoln Pharmaceuticals Ltd is 17.6 %.

What is the ROE of Lincoln Pharmaceuticals Ltd?

The ROE of Lincoln Pharmaceuticals Ltd is 13.0 %.

What is the Face Value of Lincoln Pharmaceuticals Ltd?

The Face Value of Lincoln Pharmaceuticals Ltd is 10.0.